

# Hematological findings in lysosomal storage disorders: a perspective from the medical laboratory

Andrés Felipe Leal<sup>1</sup>, Wendy G. Nieto<sup>2</sup>, Estephania Candelo<sup>3,5,6</sup>,  
Harry Pachajoa<sup>3,4,6</sup>, Carlos Javier Alméciga-Díaz<sup>1</sup>

<sup>1</sup> Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., Colombia

<sup>2</sup> Translational Biomedical Research Group, Centro de Investigaciones, Fundación Cardiovascular de Colombia, Santander, Colombia

<sup>3</sup> Department of Medical Basic Sciences, Faculty of Health Sciences, Universidad Icesi, Cali, Colombia

<sup>4</sup> Department of Medical Genetics, Fundación Valle del Lili, Cali, Colombia

<sup>5</sup> Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia

<sup>6</sup> Congenital Abnormalities and Rare Disease Centre (CIACER), Cali, Colombia

## ARTICLE INFO

### Co-corresponding authors:

Andrés Felipe Leal, B.Sc., M.Sc.

Carlos J. Alméciga-Díaz, BPharm, Ph.D.

Institute for the Study of Inborn Errors  
of Metabolism, Faculty of Science

Pontificia Universidad

Javeriana, Cra. 7 No. 43-82

Building 54, Room 305A

Bogotá D.C., 110231

Colombia

Tel: +57-1 3208320 Ext 4140

Fax: +57-1 3208320 Ext 4099

E-mail: [lealb.af@javeriana.edu.co](mailto:lealb.af@javeriana.edu.co)

E-mail: [cjalmeciga@javeriana.edu.co](mailto:cjalmeciga@javeriana.edu.co)

### Key words:

Alder-Reilly abnormalities, hematological  
alterations, leukocyte morphology,  
lysosomal storage disorders

## ABSTRACT

Lysosomal storage disorders (LSDs) are a group of rare and genetic diseases produced by mutations in genes coding for proteins involved in lysosome functioning. Protein defect leads to the lysosomal accumulation of undegraded macromolecules including glycoproteins, glycosaminoglycans, lipids, and glycogen. Depending on the stored substrate, several pathogenic cascades may be activated leading to multisystemic and progressive disorders affecting the brain, eye, ear, lungs, heart, liver, spleen, kidney, skin, or bone. In addition, for some of these disorders, hematological findings have been also reported. In this paper, we review the major hematological alterations in LSDs based on 56 case reports published between 2010 and 2020. Hematological alterations were reported in sphingolipidosis, mucopolysaccharidoses, mucopolipidoses, neuronal ceroid

lipofuscinosis, glycogenosis, glycoproteinosis, cystinosis, and cholesteryl ester storage disease. They were reported alterations in red cell lineage and leukocytes, such as anemia and morphology changes in eosinophils, neutrophils, monocytes, and lymphocytes. In addition, changes in platelet counts (thrombocytopenia) and leukocyte abnormalities on non-peripheral blood samples were also reported for some LSDs. Although in most of the cases these hematological alterations are not pathognomonic of a specific disease or group of LSDs, since they can be easily identified in general clinical laboratories, their identification may contribute to the diagnosis of these disorders. In this sense, we hope that this review contributes to

the awareness of the importance of hematological alterations in the diagnosis of LSDs.



## 1. INTRODUCTION

Lysosomal storage disorders (LSDs) are a group of monogenic metabolic diseases produced by mutations in genes encoding for proteins involved in the lysosomal function. These mutations lead to the synthesis of proteins with none or reduced activity, producing the progressive accumulation of partially degraded substrates into the lysosome [1]. Although the clinical, diagnostics, and pathophysiology can be heterogeneous, the

**Table 1** Classification of lysosomal storage disorders

Group of LSD (Accumulated substrate)	Disease	Inheritance	OMIM number
Glycogenoses (Glycogen)	Danon Disease	X-LD	300257
	Pompe Disease	AR	232300
Glycoproteinoses (Glycoproteins)	Aspartylglucosaminuria Disease	AR	208400
	Fucosidosis	AR	230000
	Galactosialidosis	AR	256540
	α-Mannosidosis	AR	248500
	β-Mannosidosis	AR	248510
	Schindler Disease	AR	609241
Mucopolysaccharidoses (Glycosaminoglycans)	Sialidosis	AR	256550
	Mucopolipidoses (Mucolipids)	Type I-IV	AR
Mucopolysaccharidoses (Glycosaminoglycans)	Type I (Hurler Syndrome)	AR	607014

	Type II (Hunter Syndrome)	X-LR	309900
	Type III (Sanfilippo Syndrome)	AR	252920
	Type IV (Morquio Syndrome)	AR	253000
	Type VI (Maroteaux -Lamy Syndrome)	AD	184095
	Type VII (Sly Syndrome)	AR	253220
	Type IX (Natowicz Syndrome)	AR	601492
	*MPS-Plus syndrome	AR	617303
Neuronal ceroid lipofuscinoses (Lipofuscin)	Type I – VIII	AR	256730
Sphingolipidoses (Sphingolipids)	Fabry Disease	X-L	301500
	Farber Disease	AR	228000
	Gaucher Disease	AR	231000
	GM1 Gangliosidoses	AR	230500
	GM2 Gangliosidoses	AR	272800
	Metachromatic leukodystrophy	AR	250100
	Niemann-Pick A, B, C	AR	257200
	Krabbe Disease	AR	245200
Unclassified LSD	Cystinosis	AR	219750
	Cholesteryl ester storage disease	AR	278000
	Free sialic acid deposition disorders	AR	269920
	Multiple sulphatase deficiency	AR	272200
	Pycnodysostosis	AR	265800

AR: Autosomal recessive. X-LD: X-linked dominant. X-LR: X-linked recessive. \*Recently described in Turkish and Yakut (Russian) patients (See [13]). Note that MPS V (Sheie syndrome) is not included in the table since it was later recognized as an attenuated form of MPS I. Similarly, MPS VIII is not included since after being proposed, it was recognized as a laboratory pitfall and the proposal was withdrawn [14].

LSDs can be classified into 7 groups according to the accumulated general substrate (Table 1).

The diagnosis of a LSDs is based on clinical evaluation of the patient and laboratory tests such as the evaluation of the enzymatic activity [2], or the primary stored substrate (e.g., glycosaminoglycans, oligosaccharides, sphingolipids, and glycogen, among others) [3, 4]. Molecular diagnosis is still difficult considering the lack of complete understanding of the clinical implications of novel variants [5-7]. Nevertheless, molecular diagnosis should be considered during the diagnosis of some LSDs, such as neuronal ceroid lipofuscinosis [8]. Moreover, lyso-Gb3 for Fabry disease (FD) or macrophage inflammatory protein 1- $\alpha$  (MIP-1 $\alpha$ ) in Gaucher disease (GD) have been suggested as novel biomarkers of these LSDs [5]. Chitotriosidase has also been proposed as a biomarker for some LSDs such as GD [9], cystinosis [10], GM1 gangliosidosis [11], and Niemann-Pick type C [12]. Particularly in GD, some hematological alterations on macrophages are frequently found in both smear blood and biologic fluids (i.e., Bronchoalveolar lavage-BAL), which may contribute to the diagnosis. Nevertheless, leukocyte abnormalities also can be found in other LSDs. In this review, we described the major hematological alterations in LSDs found in 56 case reports published between 2010 and 2020. Reference values of all hematological findings were adjusted to the guidelines on standard operating procedures for hematology of the World Health Organization (WHO).

## **2. LSD AND GENERAL DIAGNOSIS**

Lysosomes were first described in the 1950s by Christian De Duve, who recognized the role of this organelle in the degradation and recycling of intracellular and extracellular macromolecules [15]. During the last decade, they have been recognized other lysosomal functions due to the fundamental role as a metabolic hub, influencing

and sensing diverse nutrient processes, secretion, gene regulation, plasmatic membrane repair, ionic homeostasis, immune response, and cholesterol transport, among others [16]. The lysosomal biogenesis is triggered by the transcription factor EB (TFEB), which is a master regulator of the lysosomal biogenesis and influences the interaction of the lysosome with other organelles and the cellular homeostasis [16].

LSDs are a group of about 70 monogenic metabolic disorders caused by the deficiency of a specific protein (i.e., enzyme, transporter, or cofactor) involved in the lysosomal function. This deficiency leads to the lysosomal accumulation of partially degraded substrates that generates and spectrum of clinical manifestations depending of the stored substrate and the affected tissues [17]. LSDs have an overall prevalence between 1 in 4,000 and 7,000 live births. Nevertheless, the exact prevalence of LSDs is difficult to calculate due to their wide heterogeneity, which sometimes leads to misdiagnosis [5]. An important group of LSDs are associated with central nervous system (CNS) impairment, while others are mainly characterized by their effect on peripheral organs. The reader is referred to recent review for more details about LSDs [18].

## **3. DIAGNOSIS**

Given the enormous heterogeneity found in the LSDs, the diagnosis is always a challenge, and it requires a common effort between clinicians, biochemists, and medical laboratory scientists to achieve an adequate and timely diagnosis. In this sense, clinical suspicion should be accompanied by accurate routine and specialized laboratories.

### **3.1 Clinical approach**

LSDs clinical manifestation mainly depends on the stored substrate and the affected tissues.

Usually, the storage substrate occurs in the organs where the substrate is synthesized (i.e., liver, spleen, bone, brain, muscle). In this sense, the accumulation of the substrate will generate a disruption of the cellular homeostasis, inducing cellular damage, mitochondrial stress, apoptosis, dysregulation of redox processes, and disruption of the lysosome in/out transport [19-21]. Phenotypic features of patients with LSDs vary depending of the stored substrate and may include coarse face, short stature, skeletal abnormalities, hepatosplenomegaly, cardiac and lung disease, eye and ear impairment, and central nervous system involvement [5, 18].

### 3.2 Laboratory approach

As previously noted, the diagnostic confirmation of a LSD requires a specialized laboratory including the identification of biomarkers (e.g., stored substrate quantitation), determination of enzymatic activities, and molecular diagnosis. In these scenarios, important advances have been reached. For instance, the measure of GAGs by several qualitative and quantitative methods such as alcian blue, toluidine blue, paper, and thin-layer chromatography, high-pressure chromatography, gas chromatography, mass spectrometry is used in MPS diagnosis and follow up [22]. Collagen type II,  $\beta$ -galactosidase, nidogen-1, and fatty acid-binding protein are also used in MPS [23]. For FD, it has been proposed the globotriaosylsphingosine determination, whereas the measure of chitotriosidase is used for GD. Other biomarkers for GD include glucosylsphingosine, macrophages protein 1-alpha and 1-beta, cathepsin K and osteopontin [23]. For sphingolipidoses such as Krabbe, the psychosine has been described as a biomarker, which may determine the progression of the disease [23], whereas the cholestane-3 $\beta$ , 5 $\alpha$ , 6 $\beta$ -triol (C-triol), and 7-ketcholesterol seem to be a sensible biomarker in Niemann-Pick type C (NPC) [24,

25]. In glycogenoses, as in Pompe disease, the most known biomarker is tetrasaccharide glucose (Glc4), which correlates with therapy response. Other two biomarkers, myostatin and insulin-growth factor I (IGF-I), can also be used in Pompe disease [23, 26]. These biomarkers could be useful in pseudo-deficiencies, as reported for MPS I, MPS VII, and GD [27, 28], for which the traditional biochemical tests not always lead to a specific diagnosis. The enzyme activity determination is the gold standard for the diagnosis of LSDs produced by the impairment of an enzyme. This activity can be assayed in a wide range of biological samples such as plasma, serum, leukocytes, cultured fibroblasts, chorionic villi, amniotic fluid, cultured amniocytes, and dried blood spots [29]. Finally, the molecular diagnosis can help to establish the diagnosis and genetic counseling interventions [3], and is the gold standard for other conditions as neuronal ceroid lipofuscinosis [8]. Nevertheless, biomarker-, enzyme activity-, or molecular-based diagnosis of LSDs requires highly specialized facilities and trained personnel. In contrast, the analysis of the hematological abnormalities, which can help in the diagnosis of some LSDs, can be performed in low and high-complexity laboratories. In this sense, in the next sections, we will review the complexity of the hematopoietic system and the major alterations reported in some LSDs.

## 4. OVERVIEW OF THE HEMATOPOIETIC SYSTEM


Hematopoietic stem cells (HSC) are considered the foundation of the adult hematopoietic system and have a crucial role in the long-term maintenance and production of all mature blood cell lineages. Pioneering studies by Till and McCulloch, 1960 and Becker *et al.*, 1963; using transplantation experiments demonstrated the clonality of the adult hematopoietic system

and indicated that the majority of blood cells originate from very few/unique multipotent HSCs capable of proliferation, differentiation, and self-renewal [30]. These HSC-independent hematopoietic cells originate in the embryo and persist in the adult hematopoietic system [31, 32]. Whereas thrombopoietin, erythropoietin, colony-stimulating factor, and some interleukins promote the HSCs proliferation; several

cytokines promote the HSC differentiation into multipotential colony-forming progenitor units (CFU) including: CFU-GEMM (Granulocytes, Erythrocytes, Monocytes, Megakaryocytes) for the myeloid lineage and CFU-Li (T, B or NK cells) for the lymphoid lineage (Figure 1) [33, 34].

Since mature blood cells derived from HSC contain all the eukaryotic organelles, including lysosome, substrate accumulation observed in LSDs

**Figure 1** Hematopoietic landscape. HSCs are cells with unique characteristics of self-renewal, pluripotency, and differentiation



Several pathways have been described like positive (+) and negative (-) modulators of self-renewal [35, 36]. Upon intrinsic and extrinsic signals (cytokines, growth factors, and transcription factors), HSCs can give origin to GFU-GEMM and CFU-Li to myeloid and lymphoid precursors, respectively [37]. In contrast with the BM, where the blood cells precursors are present, in the bloodstream only mature cells are found which are virtually distributed around the body. All the blood cells, except the erythrocyte and platelets, maintain their organelles including the lysosomes. This figure was created using [BioRender.com](https://www.biorender.com).

can affect not only the hematopoietic precursors but also the most differentiated cells as red blood cells, leukocytes, and thrombocytes or even platelets [38, 39]. In Table 2, we summarize

the normal values for the blood count and in the next sections, we describe the normal findings of the blood cells as well as their alteration in the LDS context.

**Table 2** Reference values of hemogram

Lineage	Parameter	Units	0-2 years	2-5 years	Men	Women	
Red cell lineage	Red blood cells	Cells/ $\mu$ L	4.5 $\pm$ 0.8	4.6 $\pm$ 0.7	5 $\times$ 10 <sup>6</sup>	4.5 $\times$ 10 <sup>6</sup>	
	Hemoglobin	g/L	120 $\pm$ 15	125 $\pm$ 10	140 - 175	123 - 153	
	Hematocrit	%	36 $\pm$ 3	37 $\pm$ 3	42 - 50	36 - 45	
	MCV	fL	78 $\pm$ 8	81 $\pm$ 6	87 $\pm$ 7		
	MHC	pg	27 $\pm$ 4	27 $\pm$ 3	29 $\pm$ 2		
	RDW	%	13.6 $\pm$ 2	12.8 $\pm$ 1.2	13 $\pm$ 1.5		
	Reticulocytes	%	1.0 $\pm$ 0.8			<2	
Leukocytes	Leukocyte count	Cells/ $\mu$ L	6 $\times$ 10 <sup>3</sup> - 7 $\times$ 10 <sup>3</sup>	5.5 $\times$ 10 <sup>3</sup> - 15.5 $\times$ 10 <sup>3</sup>	4 $\times$ 10 <sup>3</sup> - 11 $\times$ 10 <sup>3</sup>		
	Lymphocytes	Cells/ $\mu$ L	3 $\times$ 10 <sup>3</sup> - 9.5 $\times$ 10 <sup>3</sup>	2 $\times$ 10 <sup>3</sup> - 8 $\times$ 10 <sup>3</sup>	1 $\times$ 10 <sup>3</sup> - 4 $\times$ 10 <sup>3</sup>		
		%	44 - 74	35 - 65	20 - 40		
	Monocytes	Cells/ $\mu$ L	0.5 $\times$ 10 <sup>3</sup>			0,15 $\times$ 10 <sup>3</sup> - 0,9 $\times$ 10 <sup>3</sup>	
		%	5			2-8	
	Neutrophils	Cells/ $\mu$ L	1,5 $\times$ 10 <sup>3</sup> - 8,5 $\times$ 10 <sup>3</sup>			2,5 $\times$ 10 <sup>3</sup> - 8,0 $\times$ 10 <sup>3</sup>	
		%	15 - 45	25 - 57	55 - 65		
Eosinophils	Cells/ $\mu$ L	0,3 $\times$ 10 <sup>3</sup>			0,05 $\times$ 10 <sup>3</sup> - 0,5 $\times$ 10 <sup>3</sup>		
	%	3			1 - 3		
Basophils	Cells/ $\mu$ L	0,1 $\times$ 10 <sup>3</sup>			0,025 $\times$ 10 <sup>3</sup> - 0,1 $\times$ 10 <sup>3</sup>		
	%	0 - 1					
Platelets	Platelets	Cells/ $\mu$ L	200 $\times$ 10 <sup>3</sup> - 400 $\times$ 10 <sup>3</sup>		150 $\times$ 10 <sup>3</sup> - 450 $\times$ 10 <sup>3</sup>		

Values have been adjusted from WHO guidelines [40].

## 5. HEMATOLOGICAL ABNORMALITIES IN LSDS

We found a total of 51 articles that included 56 LSDs cases in which hematological parameters were evaluated. The reported cases included 26 sphingolipidosis, 13 MPS, 3 ML, 3 neuronal ceroid lipofuscinosis (NCL), 2 glycogenosis, 2 glycoproteinosis, 1 cystinosis, 1 cholesteryl ester storage disease (CESD), and 1 unclassified LSDs. Male patients were more frequently reported than females (57.2% male vs 42.8% female). The age for male patients was between 2 weeks and 68 years; whereas females ranged from newborn to 69 years. We focused on the hematological parameters before the establishment of any clinical intervention to identify baseline values and morphological changes in blood cells that could be associated with the disease. All data is summarized in Table 3.

### 5.1 Red cell lineage

Anemia was reported in 30.3% of the cases (17/56), with GD having the highest number of reports (64.7%), followed by cystinosis, CESD, NPC, ML IV, MPS I, and aspartylglucosaminuria, with 5.9% each one. Based on the MCV, 3 cases of microcytic anemia (MCV <80fL) were identified, all of them corresponding to GD. Although mild anemia was the main finding, one case reported a severe microcytic hypochromic anemia (Hb: 50 g/L; MCV: 66 fL, MCH: 19.4 pg) in a 1-year-old man diagnosed with GD type 1 with slight anisocytosis and poikilocytosis [41]. Interestingly, a 69 years-old Japanese female with GD type 1 and gastric cancer had a reduction in the erythrocytes count ( $3.98 \times 10^6/\mu\text{L}$ ) and hematocrit levels (34,6%), with marked reticulocytosis (20%) [42]. In this patient, a novel mutation c.587A>G (p.K157R) in the *GBA* gene was reported; however, the impact of this mutation on the  $\beta$ -glucocerebrosidase was not evaluated.

### 5.2 Leukocytes

As previously described, LSDs are a group of metabolic disorders characterized by substrate accumulation into the lysosome [1]. In this sense, it could be expected that the major hematological findings are related to the leukocyte morphology due to the presence of organelles in these cells [43]. The reader is referred to some of the reviewed publications for representative images of leukocytes alterations [44-48].

#### 5.2.1 Granulocytes

Basophil abnormalities were not reported on any of the revised cases. On the other hand, eosinophils with enlarged and sparse granules in the blood smear were reported in three cases of GM1 gangliosidosis [44, 49, 50]. Although these alterations have been recognized since early reports as frequent alterations of GM1 gangliosidosis [51], they are not routinely investigated as part of suspicion of GM1 gangliosidosis unless the absolute leukocyte count is altered. Eosinophils with deep pink-blue granules were reported in a MPS type VI female patient, as well as abnormal lobulation on neutrophils [52]. These findings were observed after an alteration in the automated analysis, which led to a suspicion that was later confirmed as pseudo-basophilia. On the other hand, the Alder-Reilly anomaly was identified on neutrophils from MPS I, IV, and VI patients [45, 52-55], representing a potential finding for this LSD group. Although we did not find the Alder-Reilly anomaly in the reports for other LSDs, it is not possible to discard its presence in entities different than MPS. In addition, Alder-Reilly inclusions must not be confused with toxic granulations that are restricted to neutrophils in a transitory form during an inflammatory process [43].

#### 5.2.2 Monocytes

Despite the crucial role of monocytic cells, morphology alterations were not frequently

reported in the peripheral blood of LSDs patients. However, some dense blue/purple-black granules have been occasionally reported in monocytes from MPS patients [54, 55], which are metachromatic after toluidine staining [46]. Nevertheless, the most common findings on monocytes seem to be restricted to the phagocytic activity of the macrophages from BM, liver, and spleen. These changes will be discussed later.

### 5.2.3 Lymphocytes

Morphologic alterations in lymphocytes were reported in almost all the LSDs cases reviewed. Vacuolated lymphocytes were reported in GM1 gangliosidosis [49, 56], ML [57], and MPS III [58]. This vacuolization was accompanied by Alder-Reilly inclusions in MPS IIIA [47], MPS IIIB [59], MPS IV [54] and MPS VII [59]. In ML type II (I-cell disease) vacuole-like inclusions are frequently observed on lymphocytes, in which accumulation of HLA class II molecules have been observed, suggesting a role of N-acetylglucosamine-1-phosphotransferase in the immune system [60]. In this sense, the study of the chemical nature of the inclusions may increase our knowledge about the pathophysiology of the disease and lead to the identification of novel therapeutic targets. On the other hand, atypical and reactive states of lymphocytes were reported in one case of GD [61] and aspartylglucosaminuria [62], respectively. Also, electronic microscopy of peripheral blood samples allowed the identification of cytoplasmic vacuoles containing electron-dense periodic structures in lymphocytes from NCL patients [63-65].

In Pompe disease, it has been reported that vacuolation of lymphocytes [66] is a consequence of the lysosomal glycogen accumulation [67]. Electronic microscopy of peripheral blood cells, allowed the identification of inclusions in samples from Pompe disease patients [68]. Despite

vacuolization is being suggestive of lysosomal storage, the use of a specific glycogen staining (i.e., periodic acid-Schiff, PAS), allows a more accurate diagnostic impression. This was validated by Hagemans *et al.*, through the analysis of PAS-stained blood films obtained from 65 patients with classical infantile and adult forms of Pompe disease, with a sensitivity and specificity of 100% and 98%, respectively [69].

### 5.3 Platelets

We found platelet counts in 25 out of the 56 case reports reviewed. In 60% of the cases (15/25), it was reported a marked thrombocytopenia ( $< 95 \times 10^3$  cells/ $\mu$ L), without abnormalities in the morphology. Although most of the reports are from GD patients (7/15) [48, 70, 71], it was also reported in Niemann-Pick type B [72] and C [73]; MPS II [74], MPS VII [75], aspartylglucosaminuria [62], and cystinosis [76]. One case of thrombocytosis ( $595 \times 10^3$  cells/ $\mu$ L) was reported in a 5-month-old female Pompe disease patient [66], whereas in one case the use of electronic microscopy allowed the visualization of granular inclusions on platelets from a 59-year-old Pompe disease patient [68].

### 5.4 Leukocyte abnormalities on non-peripheral blood cells

The major goal of this review article was to describe the more common hematological findings in LSDs with a particular focus on the blood smear due to its routine use in medical laboratories. Nevertheless, interesting changes of leukocytes, particularly in monocyte-derived lineage, have been registered in several biological samples which are summarized in Table 4. For instance, for GD it has been described the presence of Gaucher cells in BM [80, 86]. Gaucher cells are very large cells, usually macrophages, with a diameter between 20 and 80  $\mu$ m with a small and eccentrically placed nucleus as well as a cytoplasm with wrinkles or striations [87].

**Table 3** Summary of hematological abnormalities in LSDs patients

LSD	Red cell lineage	White line				Platelets	Ref.
		Eosino-phils	Neutro-phils	Mono-cytes	Lympho-cytes		
Gaucher	Anemia				Atypical	Thrombocytopenia	[41, 48, 61, 70, 71, 77-80]
Niemann-Pick	Anemia					Thrombocytopenia	[72, 73, 81, 82]
GM1 Gangliosidoses		Enlarged and sparse granules			Vacuolated		[44, 49, 50, 56]
Pompe					PAS-positive vacuoles	Thrombocytosis	[66, 68, 69]
Cystinosis	Anemia					Thrombocytopenia	[76]
CESD	Anemia						[83]
MPS I			AR				[45]
MPS II			AR			Thrombocytopenia	[53, 74]
MPS III A-B					Vacuoles with AR		[47, 58, 59]
MPS IV			AR	Blue/purple-black granules	AR		[54]
MPS VI		Deep pink-blue granules	Abnormal lobulation and AR	Red-violet granules			[46, 52, 55]
MPS VII					Vacuoles with AR	Thrombocytopenia	[75, 84]
ML II					Vacuolated		[57, 60]
ML IV	Anemia						[85]
Asp.	Anemia				Reactive	Thrombocytopenia	[62]

MPS: Mucopolysaccharidosis. ML: Mucopolipidosis. CESD: Cholesteryl ester storage disease. AR: Alder-Reilly anomaly. Asp: Aspartylglucosaminuria.

**Table 4** Leukocyte abnormalities in non-peripheral blood samples from LSD patients

Sample	Technique	Leukocyte lineage	Findings	LSD	Reference
<b>BM</b>	GS	Myeloid	Histiocytes containing refractile crystal in the cytoplasm	Cystinosis	[76]
	HES	Myeloid	*Gaucher cells	Gaucher disease	[41, 48, 77, 79, 86, 92, 93]
	EM	Myeloid	*Gaucher cells	Gaucher disease	[80]
	APS	Myeloid	Histiocytes strongly positive	Gaucher disease	[42]
	GS	Myeloid	Foamy macrophages	Niemann Pick disease	[81, 88]
	TBS	Myeloid	Macrophages with metachromatic granules	MPS III	[58]
	WRS/GS	Lymphoid	**Azurophilic inclusions type dots or commas in plasma cells	MPS IIIA	[47]
<b>Spleen</b>	HES	Myeloid	*Gaucher cells	Gaucher disease	[70]
<b>BAL</b>	PPS	Myeloid	Foamy macrophages	Niemann Pick disease	[89]
<b>Liver biopsy</b>	NA	Myeloid	Foamy macrophages	Niemann Pick disease	[90]
<b>CSF</b>	WRS/GS	Myeloid	Intracytoplasmic granules in macrophages with haloes	MPS I	[91]

*BM: Bone marrow. BAL: Bronchoalveolar lavage. CSF: Cerebrospinal fluid. MPS: Mucopolysaccharidosis. NA: Not available. GS: Giemsa staining. HES: hematoxylin and eosin staining. EM: Electron microscopy. APS: Acid phosphatase stain. TBS: Toluidine blue staining. WRS: Wright staining. PPS: Papanicolaou stain. \*Despite these cells could be suggestive of Gaucher disease, the presence of pseudo-Gaucher cells in bone marrow can address an erroneous diagnosis impression when routine hematoxylin-eosin staining is performed. To identify true Gaucher cells, iron staining is recommended and typically the presence of diffuse iron staining should be observed in Gaucher cells which is absent on pseudo-Gaucher cells [94]. \*\*These findings are compatible with MPS I, II, and III when are present on peripheral lymphocytes; however, if these inclusions are found in plasma cells on bone marrow the major clinical suspicion is MPS III.*

Likewise, in Niemann Pick disease type B and C foamy macrophages have been observed in BM, bronchoalveolar lavage, and liver biopsy [88-90]. Histiocytes with refractile crystal in BM [76], and macrophages with intracytoplasmic granules in cerebrospinal fluid [91], were found in cystinosis and MPS I, respectively. Finally, azurophilic inclusions in plasma cells were found in BM from MPS IIIA patients [47].

## 6. CONCLUSIONS AND PERSPECTIVES

In LSDs, the accumulation of undegraded macromolecules into the lysosome triggers complex pathogenetic cascades leading to the clinical manifestations of these diseases. Impaired metabolism of lysosomal substrates may affect the autophagic-lysosomal system, the ubiquitin-proteasome system, the lysosome membrane permeability, and promotes inclusion body formation, dysregulation of the signaling pathway, inflammation, calcium homeostasis abnormalities, mitochondrial dysfunction, and oxidative stress [18].

These cellular changes may affect several tissues leading to different clinical manifestations, including hematological alterations. Although these hematological alterations may not be common findings in LSDs, they may contribute to the diagnosis of the disease, especially considering that the tests to evaluate these hematological abnormalities are available in most clinical laboratories. Nevertheless, health care professionals need to be aware of hematological alterations and correlate them with patient symptoms and other clinical laboratory results. In addition, it is necessary to extend the study of hematological alterations to other LSDs to explore the potential of these abnormalities as a biomarker for diagnosis or treatment follow-up.



## Research funding

A.F.L. received a doctoral scholarship from Pontificia Universidad Javeriana. C.J.A.D was supported by the Ministry of Science, Technology, and Innovation, Colombia (Grant ID 120380763212 – PPTA # 8352), Pontificia Universidad Javeriana (PPTA # 8275, 20289, and 20300), and the National MPS Society (PPTA # 9507).

## Author contributions

A.F.L., W.G.N., E.C., H.P., wrote the original draft. A.F.L., C.J.A.D., reviewed and edited the manuscript. All authors contributed to the literature analysis. All authors have read and approved the final manuscript.

## Competing interests

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the review.



## REFERENCES

1. Leal, A.F., et al., Lysosomal storage diseases: current therapies and future alternatives. *J Mol Med (Berl)*, 2020: p. 931-946.
2. Mokhtariye, A., et al., Diagnostic methods for Lysosomal Storage Disease. *Rep Biochem Mol Biol*, 2019. 7(2): p. 119-128.
3. Filocamo, M. and A. Morrone, Lysosomal storage disorders: molecular basis and laboratory testing. *Hum Genomics*, 2011. 5(3): p. 156-69.
4. Winchester, B., Lysosomal diseases: diagnostic update. *J Inherit Metab Dis*, 2014. 37(4): p. 599-608.
5. Poswar, F.O., et al., Lysosomal diseases: Overview on current diagnosis and treatment. *Genet Mol Biol*, 2019. 42(1 suppl 1): p. 165-177.
6. Bekri, S. Laboratory diagnosis of lysosomal storage diseases. 2006 [cited 2020 October/13]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK11594/>.

7. Giugliani, R., et al., Current molecular genetics strategies for the diagnosis of lysosomal storage disorders. *Expert Rev Mol Diagn*, 2016. 16(1): p. 113-23.
8. Gheldof, A., et al., Clinical implementation of gene panel testing for lysosomal storage diseases. *Mol Genet Genomic Med*, 2019. 7(2): p. e00527.
9. Sperb-Ludwig, F., et al., Chitotriosidase on treatment-naïve patients with Gaucher disease: A genotype vs phenotype study. *Clin Chim Acta*, 2019. 492: p. 1-6.
10. Veys, K.R.P., et al., Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis. *J Am Soc Nephrol*, 2020. 31(5): p. 1092-1106.
11. Arash-Kaps, L., et al., The Clinical and Molecular Spectrum of GM1 Gangliosidosis. *J Pediatr*, 2019. 215: p. 152-157.e3.
12. Sitarska, D. and A. Ługowska, Laboratory diagnosis of the Niemann-Pick type C disease: an inherited neurodegenerative disorder of cholesterol metabolism. *Metab Brain Dis*, 2019. 34(5): p. 1253-1260.
13. Vasilev, F., A. Sukhomyasova, and T. Otomo, Mucopolysaccharidosis-Plus Syndrome. *Int J Mol Sci*, 2020. 21(2).
14. Giugliani, R., et al., Overview of Mucopolysaccharidoses: Diagnosis, Natural History, Clinical pictures, in *Mucopolysaccharidoses Update (2 Volume Set)*, S. Tomatsu, et al., Editors. 2018, Nova Science Publishers, Inc.: Hauppauge, NY. p. 17-19.
15. DE DUVE, C., et al., Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J*, 1955. 60(4): p. 604-17.
16. Bajaj, L., et al., Lysosome biogenesis in health and disease. *J Neurochem*, 2019. 148(5): p. 573-589.
17. Sun, A., Lysosomal storage disease overview. *Annals of translational medicine*, 2018. 6(24): p. 476.
18. Parenti, G., D.L. Medina, and A. Ballabio, The rapidly evolving view of lysosomal storage diseases. *EMBO Mol Med*, 2021. 13(2): p. e12836.
19. Myerowitz, R., R. Puertollano, and N. Raben, Impaired autophagy: The collateral damage of lysosomal storage disorders. *EBioMedicine*, 2021. 63: p. 103166.
20. Stepien, K.M., et al., Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review. *J Clin Med*, 2020. 9(8).
21. Fecarotta, S., et al., Pathogenesis of Mucopolysaccharidoses, an Update. *Int J Mol Sci*, 2020. 21(7).
22. Kubaski, F., et al., Glycosaminoglycans detection methods: Applications of mass spectrometry. *Mol Genet Metab*, 2017. 120(1-2): p. 67-77.
23. Bobillo Lobato, J., M. Jiménez Hidalgo, and L.M. Jiménez Jiménez, Biomarkers in Lysosomal Storage Diseases. *Diseases*, 2016. 4(4).
24. Hammerschmidt, T.G., et al., Molecular and biochemical biomarkers for diagnosis and therapy monitoring of Niemann-Pick type C patients. *Int J Dev Neurosci*, 2018. 66: p. 18-23.
25. Boenzi, S., et al., Evaluation of plasma cholestane-3 $\beta$ ,5 $\alpha$ ,6 $\beta$ -triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism. *J Lipid Res*, 2016. 57(3): p. 361-7.
26. Chien, Y.H., et al., Myostatin and insulin-like growth factor I: potential therapeutic biomarkers for pompe disease. *PLoS One*, 2013. 8(8): p. e71900.
27. Kubaski, F., et al., Neonatal Screening for MPS Disorders in Latin America: A Survey of Pilot Initiatives. *Int J Neonatal Screen*, 2020. 6(4).
28. Mashima, R. and T. Okuyama, Enzyme activities of  $\alpha$ -glucosidase in Japanese neonates with pseudodeficiency alleles. *Mol Genet Metab Rep*, 2017. 12: p. 110-114.
29. McPherson, R.A. and M.B. Pincus, Diagnósticos clínicos e tratamento por métodos laboratoriais de Henry. 2012.
30. Sharkis, S.J., Canadian stem cell scientists take the prize. *Cell*, 2005. 122(6): p. 817-9.
31. Medvinsky, A., S. Rybtsov, and S. Taoudi, Embryonic origin of the adult hematopoietic system: advances and questions. *Development*, 2011. 138(6): p. 1017-31.
32. Dzierzak, E. and A. Bigas, Blood Development: Hematopoietic Stem Cell Dependence and Independence. *Cell Stem Cell*, 2018. 22(5): p. 639-651.
33. Cheung, A.M., et al., Stem cell model of hematopoiesis. *Curr Stem Cell Res Ther*, 2006. 1(3): p. 305-15.
34. Höfer, T. and H.R. Rodewald, Differentiation-based model of hematopoietic stem cell functions and lineage pathways. *Blood*, 2018. 132(11): p. 1106-1113.
35. Duan, Z. and M. Horwitz, Gfi-1 takes center stage in hematopoietic stem cells. *Trends Mol Med*, 2005. 11(2): p. 49-52.
36. Akala, O.O. and M.F. Clarke, Hematopoietic stem cell self-renewal. *Curr Opin Genet Dev*, 2006. 16(5): p. 496-501.
37. Scharf, P., et al., Cellular and Molecular Mechanisms of Environmental Pollutants on Hematopoiesis. *Int J Mol Sci*, 2020. 21(19).
38. Benjamin, R.J. and L.S. McLaughlin, Plasma components: properties, differences, and uses. *Transfusion*, 2012. 52 Suppl 1: p. 9S-19S.

39. Mathew J, Sankar P, and V. M., Physiology, Blood Plasma. StatPearls, 2020: p. 1-7.
40. WHO. World Health Organization. Regional Office for South-East Asia. Guidelines on standard operating procedures for haematology. 2000.
41. Kim, E.A., et al., Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia. *Int J Hematol*, 2019. 109(3): p. 361-365.
42. Hosoba, S., et al., A novel mutation causing type 1 Gaucher disease found in a Japanese patient with gastric cancer: A case report. *Medicine (Baltimore)*, 2018. 97(27): p. e11361.
43. Marionneaux, S., Nonmalignant leukocyte disorders. *Rodak's Hematology*, 2020.
44. Chevalier, C. and G. Detry Vacuolated lymphocytes and abnormal eosinophils in GM1 gangliosidosis, type 1. *British journal of haematology*, 2012. 156: p. 293-293.
45. Bhuyan, P., et al., Alder-Reilly Anomaly in Hurler's Syndrome in a Neonate: A Rare Case Report. *Indian J Hematol Blood Transfus*, 2013. 29(3): p. 184-6.
46. Krishnagiri, C., et al., Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report. *Ann Diagn Pathol*, 2013. 17(1): p. 137-9.
47. Nava-Aguilera, M.L., et al., Azurophilic inclusions in lymphocytes and plasma cells: a case of Sanfilippo disease. *Br J Haematol*, 2014. 164(5): p. 618.
48. Du, X., et al., Three mutations of adult type 1 Gaucher disease found in a Chinese patient: A case report. *Medicine (Baltimore)*, 2018. 97(47): p. e13161.
49. Lynch, D.T. and D.R. Czuchlewski. Peripheral blood findings in GM1 gangliosidosis. 2016 [cited 2020 November, 15th].
50. Salama, R. and J. Zhou, Vacuolated lymphocytes signifying a metabolic disorder in an infant with developmental delay. *Clin Case Rep*, 2016. 4(1): p. 99-100.
51. Gitzelmann, R., et al., Anomalous eosinophil granulocytes in blood and bone marrow: a diagnostic marker for infantile GM1-gangliosidosis? *Eur J Pediatr*, 1985. 144(1): p. 82-4.
52. Piva, E., et al., The role of automated analyzers in detecting abnormal granulation of leucocytes in lysosomal storage diseases: Maroteaux-Lamy disease. *Am J Hematol*, 2013. 88(6): p. 527.
53. AlMozain, N. and N.A. Bakshi, A case of hunter syndrome and Alder-Reilly anomaly. *Journal of Applied Hematology*, 2017. 8: p. 33-35.
54. Jain, R., et al., Mucopolysaccharidosis: A case report highlighting hematological aspects of the disease. *J Lab Physicians*, 2019. 11(1): p. 97-99.
55. Teixeira, C., J. Barbot, and M.I. Freitas, From blood film to the diagnosis of rare hereditary disorders. *Br J Haematol*, 2015. 168(3): p. 315.
56. Vasei, M., M. Abolhasani, and M. Safavi, Vacuolated Lymphocytes as a Clue for Diagnosis of Lysosomal Storage Disease like GM1 Gangliosidosis. *Indian J Hematol Blood Transfus*, 2018. 34(4): p. 749-750.
57. Bounds, R.L., et al., Left Main Coronary Artery Atresia in an Infant With Inclusion-Cell Disease. *World J Pediatr Congenit Heart Surg*, 2018. 9(2): p. 246-250.
58. Ireland, R.M., Morphology in mucopolysaccharidosis type III: specific diagnostic features. *Blood*, 2016. 127(5): p. 662.
59. Do, L. and L. Pasalic, Lymphocytes in Sanfilippo syndrome display characteristic Alder-Reilly anomaly. *Blood*, 2019. 134(14): p. 1194.
60. Yokoi, A., et al., B-cell-specific accumulation of inclusion bodies loaded with HLA class II molecules in patients with mucopolipidosis II (I-cell disease). *Pediatr Res*, 2019. 86(1): p. 85-91.
61. Rizk, T.M., R.O. Ariganjoye, and G.I. Alsaheed, Gaucher disease. Unusual presentation and mini-review. *Neurosciences (Riyadh)*, 2015. 20(3): p. 271-6.
62. Liu, Y., et al., [A family with two children diagnosed with aspartylglucosaminuria-case report and literature review]. *Zhonghua Er Ke Za Zhi*, 2014. 52(6): p. 455-9.
63. Lau, N.K.C., et al., First case of genetically confirmed CLN3 disease in Chinese with cDNA sequencing revealing pathogenicity of a novel splice site variant. *Clin Chim Acta*, 2018. 486: p. 151-155.
64. Canafoglia, L., et al., Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation. *Epilepsia*, 2014. 55(6): p. e56-9.
65. Guerreiro, R., et al., CLN6 disease caused by the same mutation originating in Pakistan has varying pathology. *Eur J Paediatr Neurol*, 2013. 17(6): p. 657-60.
66. Bajel, A., et al., Lymphocyte vacuolation: clue to inherited metabolic disease. *Pathology*, 2010. 42: p. 699-700.
67. Morales, J. and A. Anilkumar Glycogen Storage Disease Type II (Pompe Disease). 2020.
68. Hossain, M.A., et al., A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy. *J Stroke Cerebrovasc Dis*, 2018. 27(11): p. 3046-3052.

69. Hagemans, M.L., et al., PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. *J Inherit Metab Dis*, 2010. 33(2): p. 133-9.
70. Yang, M., Fever, pulmonary interstitial fibrosis, and hepatomegaly in a 15-year-old boy with Gaucher disease: a case report. *J Med Case Rep*, 2018. 12(1): p. 306.
71. Mazher, W., et al., Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy. *J Ayub Med Coll Abbottabad*, 2018. 30(3): p. 479-481.
72. Grasko, Y., et al., A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemann-Pick disease type B presenting to a lipid disorders clinic. *Ann Clin Biochem*, 2014. 51(Pt 5): p. 615-8.
73. Kumagai, T., et al., A case of Niemann-Pick disease type C with neonatal liver failure initially diagnosed as neonatal hemochromatosis. *Brain Dev*, 2019. 41(5): p. 460-464.
74. Uz, B., H. Demiroglu, and O.I. Ozcebe, Hunter syndrome and new onset idiopathic thrombocytopenic purpura in a young patient. *Ann Hematol*, 2012. 91(2): p. 303-4.
75. Huang, Y.L., et al., [Mucopolysaccharidosis VII: report of a case and review of the literature]. *Zhonghua Er Ke Za Zhi*, 2011. 49(6): p. 455-8.
76. Lyoo, Y., X. Zhao, and C.S. Nangia, Pancytopenia in a patient with cystinosis secondary to myelosuppression from cystine crystal deposition: a case report. *J Med Case Rep*, 2015. 9: p. 205.
77. Sgherza, N., et al., Who seeks finds. Gaucher's disease: a rare case of thrombocytopenia. *Int J Hematol*, 2020. 111(3): p. 327-328.
78. Emanuel, A.J., et al., Small Bowel Mucosal Involvement and Mesenteric Mass Formation in a Young Female with Type 3 Gaucher Disease. A Case Report. *J Gastrointest Liver Dis*, 2018. 27(4): p. 459-463.
79. Ceravolo, F., et al., Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report. *J Med Case Rep*, 2017. 11(1): p. 19.
80. Lo, S.M., et al., Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. *Blood*, 2012. 119(20): p. 4731-40.
81. Bajaj, S., et al., Rare disease heralded by pulmonary manifestations: Avoiding pitfalls of an "asthma" label. *J Postgrad Med*, 2017. 63(2): p. 122-127.
82. Bermejo, N., J. Prieto, and M.J. Arcos, Sea-blue histiocytosis in bone marrow of a patient with chronic thrombocytopenia. *Acta Haematol*, 2015. 133(3): p. 277-8.
83. Canbay, A., et al., Cholesteryl Ester Storage Disease: Fatal Outcome without Causal Therapy in a Female Patient with the Preventable Sequelae of Progressive Liver Disease after Many Years of Mild Symptoms. *Am J Case Rep*, 2018. 19: p. 577-581.
84. Dubot, P., et al., First Report of a Patient with MPS Type VII, Due to Novel Mutations in GUSB, Who Underwent Enzyme Replacement and Then Hematopoietic Stem Cell Transplantation. *Int J Mol Sci*, 2019. 20(21).
85. Yamaguchi, N., et al., Novel compound heterozygous MCOLN1 mutations identified in a Japanese girl with severe developmental delay and thin corpus callosum. *Brain Dev*, 2020. 42(3): p. 298-301.
86. Erdem, N., A. Çizmecioglu, and İ. Aydoğdu, From Bone Marrow Necrosis to Gaucher Disease; A Long Way to Run. *Turk J Haematol*, 2015. 32(4): p. 373-4.
87. Gözdaşoğlu, S., Gaucher Disease and Gaucher Cells. *Turk J Haematol*, 2015. 32(2): p. 187-8.
88. Velarde-Félix, J.S., et al., Pathogenic Compound Heterozygous Mutations in a Mexican Mestizo Patient with Niemann-Pick Disease Type B. *Genet Couns*, 2016. 27(2): p. 211-7.
89. Chebib, N., F. Thivolet-Bejui, and V. Cottin, Interstitial Lung Disease Associated with Adult Niemann-Pick Disease Type B. *Respiration*, 2017. 94(2): p. 237-238.
90. Sheth, J., et al., Pulmonary manifestations in Niemann-Pick type C disease with mutations in NPC2 gene: case report and review of literature. *BMC Med Genet*, 2017. 18(1): p. 5.
91. Lukefahr, A.L. and M. Proytcheva, Alder-Reilly Anomaly in the Cerebrospinal Fluid of a Child With Hurler Syndrome. *J Pediatr Hematol Oncol*, 2018. 40(1): p. 74-75.
92. Machaczka, M., et al., Recurrent pulmonary aspergillosis and mycobacterial infection in an unsplenectomized patient with type 1 Gaucher disease. *Ups J Med Sci*, 2014. 119(1): p. 44-9.
93. Liu, L.Y., et al., A Novel Functional Missense Mutation p.T219A in Type 1 Gaucher's Disease. *Chin Med J (Engl)*, 2016. 129(9): p. 1072-7.
94. Gören Şahin, D., et al., Gaucher Cells or Pseudo-Gaucher Cells: That's the Question. *Turk J Haematol*, 2014. 31(4): p. 428-9.